---

The First Multi-Cancer Test Panel Using a Single ​Sample of Blood 

Available Initially in California

Proven Technology - Unlimited Possibilities

ARISTOTLE has been built on our proprietary mRNA technology platform, which was validated in more than 9,000 patients for the development of the first liquid biopsy for Colorectal Cancer (ColonSentry®).  ColonSentry has been used on 100,000 patients in the U.S. Our scientists are also looking to apply ARISTOTLE to disease states in Gastroenterology, Neurology, Cardiology, and Autoimmune Disorders. Aristotle was selected for online publication at the 2020 annual meeting of the American Society of Clinical Oncology (ASCO). 

Female Panel

• Breast Cancer
• Ovarian Cancer
• Bladder Cancer
• Cervical Cancer
• Endometrial Cancer​
• Liver Cancer
• Colorectal Cancer
• Stomach Cancer
• Nasopharyngeal Cancer​​​​​

Male Panel

• Prostate Cancer
• Bladder Cancer​​
• Liver Cancer
• Colorectal Cancer
• Stomach Cancer
• Nasopharyngeal Cancer​​​​

---

For Employers & Organizations

Sensitivity and Specificity

ARISTOTLE has been demonstrated to identify sets of gene transcripts capable of classifying subjects as having a specific cancer with a high degree of sensitivity and specificity.

Sources:
1) Aristotle: A single blood test for pan-cancer screening.Adam A Dempsey, Samuel Chao, Dimitri Stamatiou, Tanya Pilcz, Jay Ying, and Robert Burakoff; Journal of Clinical Oncology 2020 38:15_suppl, e15037-e15037